GCS CO., LTD is a global specialized company with a comprehensive product portfolio spanning aesthetic medical devices, including PLLA fillers, lifting threads, and medical devices. Based on its in-house GMP and ISO 13485 certified production facilities and BIO research center, the company continuously conducts research and development. Leveraging regulatory approval capabilities across multiple countries and extensive ODM/OEM business experience, GCS is expanding its competitiveness in the global market.
Through its PLLA (Poly-L-Lactic Acid) filler ‘GANA FILL’, GCS has established a stable position in the global PLLA filler market. GANA FILL has obtained European CE certification and is supplied to approximately 30 countries, including Brazil, Russia, and regions in the Middle East. Its safety and efficacy have been verified through multiple clinical studies and SCI-level publications. Based on a natural collagen regeneration mechanism, it provides a long-term skin improvement solution and continues to show steady growth in the global market.
At KIMES 2026, GCS will formally introduce its newly launched brand ‘CLAPIO’ series to domestic and international buyers, centered around the PLLA filler GANA FILL. CLAPIO is an integrated filler brand composed of the high-purity HA filler ‘Volkey’ and the PN and CaHA-based biostimulator filler ‘Konfid’, designed to simultaneously consider precise volume formation and long-term skin improvement. This represents the culmination of GCS’s accumulated formulation technology and material research capabilities.
In addition, GCS will present its lifting threads and the FDA-cleared medical plasma device ‘PLAXPOT’, further strengthening its positioning as an integrated aesthetic solution company that combines fillers and devices. PLAXPOT is designed for various skin treatment environments based on precise plasma energy control, emphasizing both safety and user convenience.
Through participation in KIMES 2026, GCS aims not only to showcase products but also to expand substantive business meetings with global buyers. In conjunction with the exhibition, GCS will host a separate event titled ‘GCS AESTHETIC LAB’ on March 17, offering demonstration-focused programs that allow global buyers and aestheticians to directly experience the operating principles and clinical applications of its plasma device. This initiative is intended to enhance product understanding and establish a foundation for post-exhibition purchase and collaboration discussions.
GCS’s primary target markets include Brazil, Russia, the Middle East (UAE, Saudi Arabia), and major European countries, where its filler and device products are already being supplied. Through this exhibition, the company plans to expand engagement with new device buyers in the Middle East and South America, aesthetic device distribution partners in Europe, and aesthetic chains and distributors in Asia.
Moving forward, GCS plans to continuously expand its global network through participation in major international exhibitions and the strengthening of local partnerships, beginning with KIMES. Based on clinical evidence and a robust quality management system, the company aims to further solidify its position as an integrated aesthetic solutions provider encompassing both fillers and devices.